{
    "clinical_study": {
        "@rank": "60303", 
        "arm_group": [
            {
                "arm_group_label": "Part A (Pilot Study)", 
                "arm_group_type": "No Intervention"
            }, 
            {
                "arm_group_label": "Monotherapy (Part B)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of\n      oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus."
        }, 
        "brief_title": "A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have been diagnosed with type 2 diabetes mellitus by a medical\n             professional according to the American Diabetes Association guidelines.\n\n          -  Hemoglobin A1c of \u22657 and \u226410.0% in subjects who are metformin-naive or have not taken\n             metformin for 2 months or Hemoglobin A1c of \u22656.5 and \u22649.5% in subjects who are\n             metformin-na\u00efve and are taking SU or DPP-IVi which is washed off or taking metformin\n             and are willing to discontinue metformin in a 8-week washout period.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine (other\n             than T2DM and hypothyroidism), gastrointestinal, cardiovascular, pulmonary, hepatic,\n             psychiatric or neurologic disease.\n\n          -  A waist circumference which makes fitting imto the bore of the MR scanner impossible.\n\n        Subjects with history of dry eye, known ocular or systemic disease that affect the sclera\n        or cornea."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792635", 
            "org_study_id": "B1731003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Monotherapy (Part B)", 
                "description": "PF-05175157 will be administered at 200 mg twice a day for 43 days.", 
                "intervention_name": "PF-05175157", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Monotherapy (Part B)", 
                "description": "Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Type 2 Diabetes Mellitus", 
            "Pharmacodynamics", 
            "Safety & Tolerability"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731003&StudyName=A%206-Week%20Study%20Of%20PF-05175157%20In%20Type%202%20Diabetes%20Mellitus"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Chula Vista", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91911"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Glucose infusion rates", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Endogenous glucose production measured by means of euglycemic hyperinsulinemic clamp", 
                "measure": "Endogenous glucose production", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "measure": "Whole-body glucose uptake", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792635"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of appearance of glucose in fasting state and during insulin infusions", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Glucose infusion rates at steady-state during Step 1 and Step 2 insulin infusions", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}